# A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens

> **NCT01009190** · PHASE1 · COMPLETED · sponsor: **pharmaand GmbH** · enrollment: 85 (actual)

## Conditions studied

- Advanced Solid Tumors

## Interventions

- **DRUG:** PF-01367338
- **DRUG:** Carboplatin
- **DRUG:** PF-01367338
- **DRUG:** Carboplatin

## Key facts

- **NCT ID:** NCT01009190
- **Lead sponsor:** pharmaand GmbH
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2010-02
- **Primary completion:** 2014-04
- **Final completion:** 2014-04
- **Target enrollment:** 85 (ACTUAL)
- **Last updated:** 2023-06-08


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01009190

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01009190, "A Study Of Poly (ADP-Ribose) Polymerase Inhibitor PF-01367338 In Combination With Several Chemotherapeutic Regimens". Retrieved via AI Analytics 2026-06-02 from https://api.ai-analytics.org/clinical/NCT01009190. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*